This technology is a rapid, highly sensitive multiplex qPCR one step assay that enables differential diagnosis of arboviruses, including Zika, Dengue, Chikungunya, and West Nile viruses.
Current diagnosis of arbovirus infections is based on the presence of symptoms, which are difficult to distinguish from those of other types of arbovirus infections. While diagnostic assays currently exist, their cross-reactivity renders differential diagnosis impossible. To circumvent this, a series of singleplex qPCR assays for individual arbovirus infections (Zika, Dengue, Chikungunya, West Nile, and others) can be performed and the results compared. However, performing individual assays is costly and time-intensive. As such, there is a need for a rapid, selective method to reliably diagnose different types of arbovirus infections.
This technology is a multiplex qPCR assay that can be performed on serum or urine, enabling concurrent evaluation of Zika, Dengue (serotype 1-4), Chikungunya, and West Nile viral infection. Unlike singleplex qPCR assays, this technology can readily distinguish between different types of infection. Additionally, this technology is compatible with multiple qPCR systems, including the BD Max, Bio-Rad, and ABI platforms.
This technology can detect fewer than 50 copies of viral DNA/RNA in a sample control and has been implemented on multiple qPCR platforms. This test, known as the CII-ArboViroPlex rRT-PCR assay, is currently approved for use under the FDA’s Emergency Use Authorization (EUA).
Patent Issued (US10,829,823)
IR CU16221
Licensing Contact: Kristin Neuman